281 related articles for article (PubMed ID: 15148104)
1. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses.
Smith KJ; Jacobson E; Hamza S; Skelton H
Arch Dermatol; 2004 May; 140(5):584-8. PubMed ID: 15148104
[TBL] [Abstract][Full Text] [Related]
2. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E; Cools J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
[TBL] [Abstract][Full Text] [Related]
3. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
4. [Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan].
Sada A; Matsui T
Rinsho Ketsueki; 2010 Jul; 51(7):515-25. PubMed ID: 20693771
[No Abstract] [Full Text] [Related]
5. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
6. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.
Cilloni D; Messa F; Martinelli G; Gottardi E; Arruga F; Defilippi I; Carturan S; Messa E; Fava M; Giugliano E; Rosso V; Catalano R; Merante S; Nicoli P; Rondoni M; Ottaviani E; Soverini S; Tiribelli M; Pane F; Baccarani M; Saglio G
Leukemia; 2007 Jul; 21(7):1442-50. PubMed ID: 17508006
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome.
Bigoni R; Cuneo A; Roberti MG; Milani R; Bardi A; Cavazzini F; Minotto C; Castoldi G
Haematologica; 2000 May; 85(5):486-91. PubMed ID: 10800164
[TBL] [Abstract][Full Text] [Related]
8. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
11. Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia.
Schaller JL; Burkland GA; Langhoff PJ
MedGenMed; 2007 Feb; 9(1):38. PubMed ID: 17435644
[TBL] [Abstract][Full Text] [Related]
12. A clonal hypereosinophilic syndrome with specific and effective therapy: a report of two cases.
Ellis MH; Ashur-Fabian O; Trakhtenbrot L; Amariglio N
Isr Med Assoc J; 2006 Dec; 8(12):836-7. PubMed ID: 17214097
[No Abstract] [Full Text] [Related]
13. [The hypereosinophilic syndrome: case report].
Mikołajczyk K; Zaba R; Walkowiak B; Grzybowski G; Samborski W
Ann Acad Med Stetin; 2006; 52 Suppl 2():65-9. PubMed ID: 17471838
[TBL] [Abstract][Full Text] [Related]
14. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.
Bain BJ
Br J Haematol; 1996 Oct; 95(1):2-9. PubMed ID: 8857931
[TBL] [Abstract][Full Text] [Related]
15. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
16. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
17. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
[No Abstract] [Full Text] [Related]
18. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
Kjeldsen E
Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
[TBL] [Abstract][Full Text] [Related]
19. Chronic eosinophilic leukemia presenting with mouth and penile ulcers.
Najera JE; Harn L
Am J Med; 2012 Aug; 125(8):e5-6. PubMed ID: 22681908
[No Abstract] [Full Text] [Related]
20. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
